UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 98

Sortiert nach

Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity

PloS one, 2017-12, Vol.12 (12), p.e0190312-e0190312

2017

Volltextzugriff (PDF)

A Method for Producing Protein Nanoparticles with Applications in Vaccines

PloS one, 2016-03, Vol.11 (3), p.e0138761-e0138761

2016

Volltextzugriff (PDF)

Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230

The Journal of biological chemistry, 2016-09, Vol.291 (38), p.19913-19922

2016

Volltextzugriff (PDF)

Determination of Protein Content in Alhydrogel ® -Based Vaccines by O-Phthalaldehyde Assay

Methods in molecular biology (Clifton, N.J.), 2017-01, Vol.1494, p.263

2017

Volltextzugriff (PDF)

Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial

The Lancet infectious diseases, 2023-11, Vol.23 (11), p.1266-1279

2023

Volltextzugriff (PDF)

Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains

Infection and immunity, 2015-10, Vol.83 (10), p.3771-3780

2015

Volltextzugriff (PDF)

Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230

Vaccine, 2020-07, Vol.38 (34), p.5480-5489

2020

Volltextzugriff (PDF)

Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1

PloS one, 2012-06, Vol.7 (6), p.e36996-e36996

2012

Volltextzugriff (PDF)

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51

PloS one, 2008-07, Vol.3 (7), p.e2636-e2636

2008

Volltextzugriff (PDF)

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission

iScience, 2023-07, Vol.26 (7), p.107192-107192, Article 107192

2023

Volltextzugriff (PDF)

mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response

npj vaccines, 2024-01, Vol.9 (1), p.9-9, Article 9

2024

Volltextzugriff (PDF)

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

PloS one, 2016, Vol.11 (10), p.e0163144-e0163144

2016

Volltextzugriff (PDF)

Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines

iScience, 2022-08, Vol.25 (8), p.104739-104739, Article 104739

2022

Volltextzugriff (PDF)

Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1

Clinical and vaccine immunology, 2017-07, Vol.24 (7)

2017

Volltextzugriff (PDF)

Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles

npj vaccines, 2023-04, Vol.8 (1), p.56-56, Article 56

2023

Volltextzugriff (PDF)

Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria

PloS one, 2012-10, Vol.7 (10), p.e46094

2012

Volltextzugriff (PDF)

Use of o -phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines

Vaccine, 2009-10, Vol.27 (43), p.6054-6059

2009

Volltextzugriff (PDF)

Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria

PloS one, 2008-08, Vol.3 (8), p.e2940-e2940

2008

Volltextzugriff (PDF)

Montanide ® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

Vaccine, 2005-03, Vol.23 (19), p.2530-2539

2005

Volltextzugriff (PDF)

Corrigendum to “Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer” [Vaccine 30 (2012) 189–194]

Vaccine, 2013-05, Vol.31 (19), p.2416-2416

2013

Volltextzugriff (PDF)

Formulation of vaccines containing CpG oligonucleotides and alum

Journal of immunological methods, 2007-06, Vol.323 (2), p.139-146

2007

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(87)

Publikationsform

Artikel
(97)
Bücher
(1)

Sprache

Englisch
(98)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Vaccine
(16)
Plos One
(9)
The Lancet Infectious Diseases
(6)
Nature
(4)
Blood
(3)
Pediatrics
(3)
The Journal Of Nutrition
(3)
Acta Paediatrica
(2)
Acta Paediatrica, International Journal Of Paediatrics
(2)
Acta Pædiatrica
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults

Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity

A Method for Producing Protein Nanoparticles with Applications in Vaccines

Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial

Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230

Determination of Protein Content in Alhydrogel ® -Based Vaccines by O-Phthalaldehyde Assay

Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial

Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains

Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230

Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission

mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines

Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1

Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles

Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria

Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA

Use of o -phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines

Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel® + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

Montanide ® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

Corrigendum to “Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer” [Vaccine 30 (2012) 189–194]

Formulation of vaccines containing CpG oligonucleotides and alum

Suchergebnisse filtern